[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"birth-control\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:birth-control":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100644200","safety-of-a-contraceptive-copper-vaginal-ring-100644200",false,"NCT07666997","Safety of a Contraceptive Copper Vaginal Ring","Prospective Elavulation of the Safety of a Novel Copper Vaginal Contraceptive Ring (CVR)","Inclusion Criteria:\n\n* Biological female\n* Age \\>18\n* Premenopausal women\n* Regular, normal, cyclic menses, with a usual length of 21 to 35 days\n* Willing to give voluntary consent, sign an informed consent form and comply with study procedures as required by the protocol\n\nExclusion Criteria:\n\n* Use of oral contraceptives, Copper-IUD, hormonal-IUD, another intravaginal contraceptive device, or any other method of female birth control within 3 months prior to study enrollment\n* Postmenopausal\n* Biological male\n* Positive urine pregnancy test at screening visit\n* Use of hormone therapy; injectable within the past 6 months; implantable within the past 3 months;\n* Presence of a vaginal\u002Fcervical\u002Futerine anomaly or a diagnosed pathology that effects the vaginal cavity and may impair the ability to safely insert\u002Fremove a vaginal ring.\n* The presence of certain conditions of relevance to vaginal ring use, such as cervicitis, vaginitis or bleeding cervical erosion; lichen sclerosis, lichen planus or vaginismus; Papanicolau (PAP) grade III-V cervical smear result; prolapse of uterine cervix, cystocele and\u002For rectocele; severe or chronic constipation, dyspareunia or other coital problems; .\n* History or current diagnosis of any of the following:\n* gynecological cancer\n* fibroids\n* polycystic ovary syndrome\n* Past exposure to radiation therapy to the pelvis, or planned radiation therapy to the pelvis during the study;\n* Current diagnosis of a sexually transmitted disease;\n* Wilson's Disease;\n* Known allergy to metal or silicone\n* Had an abortion or breastfeeding within 2 months before the start of the trial;\n* Presence of a significant medical condition or health concern that, in the opinion of the investigator, may impact the patient's safety or the study's outcomes;\n* A condition that, in the opinion of the investigator, precludes the patient from being able to provide informed consent;\n* Inability or unwillingness to refrain from using a tampon\u002Fmenstrual cup for the duration of the study.\n* Known inability to tolerate products\u002Fdevices in the vagina (i.e., tampons, menstrual cups, vaginal rings, etc.)",true,"FEMALE","18 Years","50 Years",{"count":21,"type":22},8,"ESTIMATED","INTERVENTIONAL",[25],"NA","Many birth control options today come with unwanted side effects or risks. Hormonal methods can affect both mental and physical health, while devices like copper IUDs carry risks such as uterine perforation or infection. This study is testing a new option: a copper vaginal ring (CVR) - a non-hormonal, non-invasive contraceptive that can be self-inserted, similar to a other vaginal rings like NuvaRing or Annovera.\n\nThe main goal of this study is to assess whether the copper vaginal ring is safe to use. Researchers will also look at how comfortable and easy it is to use, whether participants follow the instructions, and how much copper accumulates in cervical mucus and vaginal fluid during use.\n\nThe study will enroll 8 women of childbearing age. Participants wear the ring continuously for 28 days, inserting it on Day 5 of their menstrual cycle. Over the course of the study, participants will attend 8 in-person clinic visits, which include pelvic exams, vaginal swabs, blood draws, and cervical mucus collection. On the day the ring is removed (Day 28), small tissue samples (biopsies) are taken from the vagina and uterine lining. At the end of the study, participants will complete a short survey about their experience with the ring.",[28,29,30],"Contraception","Birth Control","Pregnancy Prevention",[32,33],"Non-hormonal","Vaginal ring","NOT_YET_RECRUITING","2026-06-19",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":22},"2026-10-01",{"date":42,"type":22},"2027-04-30",{"name":44,"class":45},"Elle, MD Biotechnologies Inc.","INDUSTRY",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100518285","international-active-surveillance-study-native-estrogen-estetrol-e4-safety-study-100518285","NCT06028555","International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study","INAS-NEES","Inclusion Criteria:\n\nNew users of E4\u002FDRSP New users of EE\u002FLNG Germany: only recruitment of study participants who are prescribed the COC within on-label use\n\nExclusion Criteria:\n\n\\-",{"count":54,"type":22},101000,"OBSERVATIONAL","Multinational, comparative, prospective, active surveillance study that follows two cohorts.\n\nThe primary objective of the study is to characterize and compare the risks of E4\u002FDrospirenone (DRSP) with levonorgestrel-containing combined oral contraceptives (EE\u002FLNG) in a study population that is representative of the actual users of these preparations. The main clinical outcome of interest is venous thromboembolism (VTE), specifically deep venous thrombosis (DVT) and pulmonary embolism (PE). Secondary objectives include measuring the occurrence of unintended pregnancy, assessing the risk of arterial thromboembolism (ATE), describing the drug utilization pattern, describing the baseline risk profile for VTE and ATE, and investigating outcomes associated with foetal exposure to E4\u002FDRSP.",[28,29],"RECRUITING","2025-08-15",{"date":61,"type":38},"2025-08-17",{"date":63,"type":38},"2023-06-28",{"date":65,"type":22},"2028-10-31",{"name":67,"class":68},"Center for Epidemiology and Health Research, Germany","OTHER",1]